Research and development on ADCC/CDC-enhanced therapeutic antibodies have dramatically increased in the past few years. However, for the reason that most ADCC/CDC antibody drugs are produced by mammalian cells, of which the production timeline is long and complex, it still a challenge for vendors to perform a reliable process and produce consistent products. Creative Biolabs provides upstream and early downstream development services that aim at delivering robust, high-yielding antibody products to our customers.

Learn more: ADCC/CDC Antibody Process Development